144 related articles for article (PubMed ID: 16202591)
21. Structural basis of specificity of a peptidyl urokinase inhibitor, upain-1.
Zhao G; Yuan C; Wind T; Huang Z; Andreasen PA; Huang M
J Struct Biol; 2007 Oct; 160(1):1-10. PubMed ID: 17692534
[TBL] [Abstract][Full Text] [Related]
22. Engineering inhibitors highly selective for the S1 sites of Ser190 trypsin-like serine protease drug targets.
Katz BA; Sprengeler PA; Luong C; Verner E; Elrod K; Kirtley M; Janc J; Spencer JR; Breitenbucher JG; Hui H; McGee D; Allen D; Martelli A; Mackman RL
Chem Biol; 2001 Nov; 8(11):1107-21. PubMed ID: 11731301
[TBL] [Abstract][Full Text] [Related]
23. Crystals of urokinase type plasminogen activator complexes reveal the binding mode of peptidomimetic inhibitors.
Zeslawska E; Jacob U; Schweinitz A; Coombs G; Bode W; Madison E
J Mol Biol; 2003 Apr; 328(1):109-18. PubMed ID: 12684001
[TBL] [Abstract][Full Text] [Related]
24. Selective urokinase-type plasminogen activator inhibitors. 4. 1-(7-sulfonamidoisoquinolinyl)guanidines.
Fish PV; Barber CG; Brown DG; Butt R; Collis MG; Dickinson RP; Henry BT; Horne VA; Huggins JP; King E; O'Gara M; McCleverty D; McIntosh F; Phillips C; Webster R
J Med Chem; 2007 May; 50(10):2341-51. PubMed ID: 17447747
[TBL] [Abstract][Full Text] [Related]
25. 3D-QSAR CoMFA studies on trypsin-like serine protease inhibitors: a comparative selectivity analysis.
Bhongade BA; Gouripur VV; Gadad AK
Bioorg Med Chem; 2005 Apr; 13(8):2773-82. PubMed ID: 15781388
[TBL] [Abstract][Full Text] [Related]
26. Plasminogen activator inhibitor-2 is highly tolerant to P8 residue substitution--implications for serpin mechanistic model and prediction of nsSNP activities.
Di Giusto DA; Sutherland AP; Jankova L; Harrop SJ; Curmi PM; King GC
J Mol Biol; 2005 Nov; 353(5):1069-80. PubMed ID: 16214170
[TBL] [Abstract][Full Text] [Related]
27. Diphenyl phosphonate inhibitors for the urokinase-type plasminogen activator: optimization of the P4 position.
Joossens J; Van der Veken P; Surpateanu G; Lambeir AM; El-Sayed I; Ali OM; Augustyns K; Haemers A
J Med Chem; 2006 Sep; 49(19):5785-93. PubMed ID: 16970403
[TBL] [Abstract][Full Text] [Related]
28. Geometry of binding of the N alpha-tosylated piperidides of m-amidino-, p-amidino- and p-guanidino phenylalanine to thrombin and trypsin. X-ray crystal structures of their trypsin complexes and modeling of their thrombin complexes.
Turk D; Stürzebecher J; Bode W
FEBS Lett; 1991 Aug; 287(1-2):133-8. PubMed ID: 1879520
[TBL] [Abstract][Full Text] [Related]
29. Quantitative RT-PCR assays for the determination of urokinase-type plasminogen activator and plasminogen activator inhibitor type 1 mRNA in primary tumor tissue of breast cancer patients: comparison to antigen quantification by ELISA.
Biermann JC; Holzscheiter L; Kotzsch M; Luther T; Kiechle-Bahat M; Sweep FC; Span PN; Schmitt M; Magdolen V
Int J Mol Med; 2008 Feb; 21(2):251-9. PubMed ID: 18204793
[TBL] [Abstract][Full Text] [Related]
30. (4-aminomethyl)phenylguanidine derivatives as nonpeptidic highly selective inhibitors of human urokinase.
Sperl S; Jacob U; Arroyo de Prada N; Stürzebecher J; Wilhelm OG; Bode W; Magdolen V; Huber R; Moroder L
Proc Natl Acad Sci U S A; 2000 May; 97(10):5113-8. PubMed ID: 10805774
[TBL] [Abstract][Full Text] [Related]
31. Synthetic urokinase inhibitors as potential antitumor drugs.
Steinmetzer T
IDrugs; 2003 Feb; 6(2):138-46. PubMed ID: 12789617
[TBL] [Abstract][Full Text] [Related]
32. Discovery of a novel conformational equilibrium in urokinase-type plasminogen activator.
Kromann-Hansen T; Louise Lange E; Peter Sørensen H; Hassanzadeh-Ghassabeh G; Huang M; Jensen JK; Muyldermans S; Declerck PJ; Komives EA; Andreasen PA
Sci Rep; 2017 Jun; 7(1):3385. PubMed ID: 28611361
[TBL] [Abstract][Full Text] [Related]
33. Elaborate manifold of short hydrogen bond arrays mediating binding of active site-directed serine protease inhibitors.
Katz BA; Elrod K; Verner E; Mackman RL; Luong C; Shrader WD; Sendzik M; Spencer JR; Sprengeler PA; Kolesnikov A; Tai VW; Hui HC; Breitenbucher JG; Allen D; Janc JW
J Mol Biol; 2003 May; 329(1):93-120. PubMed ID: 12742021
[TBL] [Abstract][Full Text] [Related]
34. Targeting urokinase-type plasminogen activator and its receptor for cancer therapy.
Nozaki S; Endo Y; Nakahara H; Yoshizawa K; Ohara T; Yamamoto E
Anticancer Drugs; 2006 Nov; 17(10):1109-17. PubMed ID: 17075310
[TBL] [Abstract][Full Text] [Related]
35. Is inhibition process better described with MD(QM/MM) simulations? The case of urokinase type plasminogen activator inhibitors.
Barbault F; Maurel F
J Comput Chem; 2012 Mar; 33(6):607-16. PubMed ID: 22241532
[TBL] [Abstract][Full Text] [Related]
36. Discrimination of different forms of the murine urokinase plasminogen activator receptor on the cell surface using monoclonal antibodies.
Rasch MG; Pass J; Illemann M; Høyer-Hansen G; Lund IK
J Immunol Methods; 2008 Nov; 339(1):55-65. PubMed ID: 18761343
[TBL] [Abstract][Full Text] [Related]
37. Expression of matrix metalloproteinases-1, -2, and -9; tissue inhibitors of matrix metalloproteinases-1 and -2; cathepsin B; urokinase plasminogen activator; and plasminogen activator inhibitor, type I in skull base chordoma.
Naka T; Kuester D; Boltze C; Schulz TO; Samii A; Herold C; Ostertag H; Roessner A
Hum Pathol; 2008 Feb; 39(2):217-23. PubMed ID: 17949787
[TBL] [Abstract][Full Text] [Related]
38. Prognostic significance of growth factors and the urokinase-type plasminogen activator system in pancreatic ductal adenocarcinoma.
Xue A; Scarlett CJ; Jackson CJ; Allen BJ; Smith RC
Pancreas; 2008 Mar; 36(2):160-7. PubMed ID: 18376307
[TBL] [Abstract][Full Text] [Related]
39. 2-(2-Hydroxy-3-alkoxyphenyl)-1H-benzimidazole-5-carboxamidine derivatives as potent and selective urokinase-type plasminogen activator inhibitors.
Mackman RL; Hui HC; Breitenbucher JG; Katz BA; Luong C; Martelli A; McGee D; Radika K; Sendzik M; Spencer JR; Sprengeler PA; Tario J; Verner E; Wang J
Bioorg Med Chem Lett; 2002 Aug; 12(15):2019-22. PubMed ID: 12113832
[TBL] [Abstract][Full Text] [Related]
40. Protease activity of urokinase and tumor progression in a syngeneic mammary cancer model.
Merchan JR; Tang J; Hu G; Lin Y; Mutter W; Tong C; Karumanchi SA; Russell SJ; Sukhatme VP
J Natl Cancer Inst; 2006 Jun; 98(11):756-64. PubMed ID: 16757700
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]